Transcript Uterine Corpus Malignancies Chemotherapy Update

Endometrial Committee
David Scott Miller, M.D., F.A.C.O.G., F.A.C.S.
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas, U.S.A.
Resected Endometrial
• GOG0249: A Phase III Trial of Pelvic
Radiation Therapy versus Vaginal Cuff
Brachytherapy Followed by
Paclitaxel/Carboplatin Chemotherapy in
Patients with High Risk, Early Stage
Endometrial Cancer
– RTOG
Resected Endometrial
• PORTEC 3: Randomized Phase III Trial
Comparing Concurrent Chemoradiation
and Adjuvant Chemotherapy with Pelvic
Radiation Alone in High Risk and
Advanced Stage Endometrial Carcinoma
– MaNGO, ANZGOG, NRCI, NCIC-CTG, NSGO
Resected Endometrial
• GOG258 (UC0704): A Randomized Phase
III Trial of Cisplatin and Tumor Volume
Directed Irradiation Followed by
Carboplatin and Paclitaxel vs. Carboplatin
and Paclitaxel for Optimally Debulked,
Advanced Endometrial Cancer
– RTOG
Pelvic Recurrence
• GOG0238: A Randomized Trial of Pelvic
Irradiation with or without Concurrent
Weekly Cisplatin in Patients with Pelviconly Recurrence of Carcinoma of the
Uterine Corpus
– RTOG, NCRI, SWOG
Advanced/Recurrent
• NCIC: EN 8: Randomized Phase III Study
of progestational hormone therapy versus
deforolimus in women with recurrent or
metastatic endometrial cancer
– ACRIN, AGO-AUST, AGO-OVAR, ANZOG,
EORTC, GEICO, GINECO, JGOG, MANGO,
MITO, NCRI, NSGO, SWOG
Carcinosarcoma
GOG0261 (UC0701): Randomized Phase
III Trial of Carboplatin plus Paclitaxel
versus Ifosfamide plus Taxol in Patients
with Advanced, Persistent or Recurrent
Carcinosarcoma
NCRI, GINECO, JGOG, RTOG
Leiomyosarcoma
• GOG0250: Randomized Phase III
Evaluation of Docetaxel, Gemcitabine, &
G-CSF +/- Bevacizumab in the Treatment
of Recurrent or Advanced
Leiomyosarcoma
GTN
• Charge from the Executive
• RFP
• ISSTD